SCHEMBL1908529

SCHEMBL1908529

CC(C)(C)NCC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22851591 0.81
SCHEMBL7614770 0.81
SCHEMBL16532931 0.79
SCHEMBL22790562 0.79 MAOA (0.34)
SCHEMBL19204201 0.79 MAOA (0.34)
SCHEMBL1717828 0.77 HMGCR (0.41)
SCHEMBL41886 0.77
SCHEMBL22805178 0.75 TDP1 (0.36)
SCHEMBL18743815 0.75 KDM4E (0.38)
SCHEMBL19944905 0.75 PIK3CD (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2950793-B1 COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES BioVersys AG (CH) 2020-04-01 EP claimed
US-9682079-B2 Composition for treatment of pathogens that are resistant to tetracyclines BioVersys AG (CH) 2017-06-20 US claimed
US-20150359791-A1 COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES BioVersys AG (CH) 2015-12-17 US claimed
EP-2950793-A1 COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES Bioversys AG (CH) 2015-12-09 EP claimed
WO-2014118361-A1 COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES BioVersys AG (CH) 2014-08-07 WO claimed
EP-2762134-A1 Composition for treatment of pathogens that are resistant to tetracyclines Bioversys AG (CH) 2014-08-06 EP claimed
WO-2008097851-A1 TETRACYCLINE COMPOSITIONS FOR TOPICAL ADMINISTRATION WARNER CHILCOTT COMPANY, INC. (US) 2008-08-14 WO claimed
WO-2008097850-A1 TRETRACYCLINE COMPOSITIONS FOR TOPICAL ADMINISTRATION WARNER CHILCOTT COMPANY, INC. (US) 2008-08-14 WO claimed
US-20080188445-A1 TETRACYCLINE COMPOSITIONS FOR TOPICAL ADMINISTRATION WARNER CHILCOTT COMPANY INC. (US) 2008-08-07 US claimed
US-20080188446-A1 TETRACYCLINE COMPOSITIONS FOR TOPICAL ADMINISTRATION WARNER CHILCOTT COMPANY INC. (US) 2008-08-07 US claimed
EP-1575947-A1 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES Amgen Inc. (US) 2005-09-21 EP claimed
US-20040147561-A1 Pyrid-2-one derivatives and methods of use SYNGENTA CROP PROTECTION AG (CH) 2004-07-29 US claimed
WO-2004060890-A1 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES AMGEN INC. (US) 2004-07-22 WO claimed
EP-0796646-B1 Method for the removal of carbon dioxide present in gases and absorbent KANSAI ELECTRIC POWER CO (JP) 2003-11-12 EP claimed
US-5904908-A USING AN AQUEOUS SOLUTION CONTAINING AN ALKYLAMINOAMIDE COMPOUND MITSUBISHI HEAVY INDUSTRIES, LTD. (JP) 1999-05-18 US claimed
EP-0796646-A1 Method for the removal of carbon dioxide present in gases and absorbent THE KANSAI ELECTRIC POWER CO., INC. (JP) 1997-09-24 EP claimed
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) 2023-11-02 US disclosed
CN-116942683-A Antimicrobial composition and application thereof 江苏奥赛康药业有限公司 2023-10-27 CN disclosed
US-5672615-A MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS NOVARTIS CORPORATION (US) 1997-09-30 US disclosed
EP-0796646-A1 Method for the removal of carbon dioxide present in gases and absorbent THE KANSAI ELECTRIC POWER CO., INC. (JP) 1997-09-24 EP disclosed